Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 5/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916799 | 0.85 | HTR5A (0.51) | HTR5ASLC9A1HTR7HTR2B | |
| SCHEMBL16502444 | 0.83 | KDM4E (0.56) | CA1CA2PARP1PARP10PARP2 | |
| SCHEMBL16502446 | 0.82 | CA1 (0.53) | CA1CA2PLAU | |
| SCHEMBL7916007 | 0.82 | HTR5A (0.41) | HTR5ASLC9A1HTR7HTR2B | |
| SCHEMBL7919380 | 0.82 | SLC9A1 (0.48) | HTR5ASLC9A1PARP1HTR7HTR2B | |
| SCHEMBL27870126 | 0.79 | KDM4E (0.60) | SLC9A1CA1CA2PARP1PARP10 | |
| SCHEMBL16502757 | 0.77 | HTR2B (0.46) | HTR5ASLC9A1HTR7HTR2B | |
| SCHEMBL9909287 | 0.75 | HTR5A (0.59) | HTR5AMAP4K4PLAU | |
| SCHEMBL3454482 | 0.74 | PARP1 (0.53) | CA1CA2PARP1PARP10PARP2 | |
| SCHEMBL7919960 | 0.74 | HTR5A (0.49) | HTR5ASLC9A1HTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | HTR5A 1/4885SLC9A1 1256/4885CA1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.